[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"health-services-research\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:health-services-research":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,42,66,94,118,130,156],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100053434","person-centered-quality-measurement-and-management-in-a-system-for-addictions-treatment-in-new-york-state-project-3-100053434",false,"NCT06408233","Person-Centered Quality Measurement and Management in a System for Addictions Treatment in New York State (Project 3)","Person-Centered Quality Measurement and Management (QM2) in a System for Addictions Treatment in New York State (Project 3)","Inclusion Criteria:\n\n* Individuals 18 years of age, and older\n* Clients and clinicians of people attending substance use treatment programs in New York State with Opioid Use Disorder in the time interval 2020-2027\n\nExclusion Criteria:\n\n* There are no exclusion criteria related to sex\u002Fgender to increase the generalizability of the findings. Children will not be included in this study because the treatment system mostly includes adults.",true,"ALL","18 Years","64 Years",{"count":21,"type":22},35,"ESTIMATED","INTERVENTIONAL",[25],"NA","The goal of this study is to implement Opioid Use Disorder Quality Measurement and Management (OUD-QM2) strategy by the Office of Addiction Services and Supports (OASAS) to drive change and improve treatment practices. Through a concurrent mixed methods approach that iteratively examines quantitative and qualitative data to inform the process, the investigators will examine the effects of the strategy on stakeholders-PWUD\u002Fpatients, families, and providers-and outcomes. This comprehensive approach will allow for a \"global\" view of the perceived effects of the OUD-QM2 strategy for all stakeholders while allowing us to use administrative data to test the effects of the strategy on patient outcomes. Through qualitative interviews and focus groups conducted in years 1, 3, and 5 of the phase, the investigators will derive information from stakeholders about their perceptions and use of the quality measures. Through surveys conducted with all clinics, the investigators will elicit data on changes in provider use of quality measures, clinical practice, and use of measures for incentive-based contracting. Finally, the investigators will conduct a stepped wedge trial to examine the effects of performance coaching that guides clinics on use of the quality measures for clinical practice improvement. The trial will also benefit from a treatment as usual (TAU) condition of clinics not participating in the trial to examine secular trends in patient outcomes across the period of the OASAS QM2 strategy rollout. The overall aim is to build and test a science-based OUD-QM2 strategy for person-centered treatment.",[28],"Health Services Research","RECRUITING","2026-07-09",{"date":32,"type":33},"2026-07-13","ACTUAL",{"date":35,"type":33},"2025-08-01",{"date":37,"type":22},"2028-12-01",{"name":39,"class":40},"NYU Langone Health","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":23,"phases":52,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":41},"100634085","phase-1-study-of-the-safety-tolerability-pharmacokinetics-and-pharmacodynamics-of-icp-538-in-healthy-subjects-100634085","NCT07535099","Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ICP-538 in Healthy Subjects","A Phase I, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Doses of ICP-538 in Healthy Participants","Inclusion Criteria:\n\n1. Voluntarily sign the ICF..\n2. BMI between 18-26 kg\u002Fm² (inclusive). Male weight ≥50 kg; female weight ≥45 kg.\n3. Vital signs, physical examination, ECG, Chest X-ray, Abdominal ultrasound results at screening are within normal range or showing minor deviations deemed not clinically significant by the investigator.\n4. Laboratory test results at screening and baseline are within the normal reference range.\n5. Reproductive Status：Females of non-childbearing potential . Male participants and their partners must agree to use effective contraception throughout the study and for 3 months after the last dose. Male participants must not donate sperm during this period.\n\nExclusion Criteria:\n\n1. Evidence or history of clinically significant diseases, or Evidence or history of allergic diseases .\n2. Clinically significant gastrointestinal dysfunction that may affect drug intake, transport, or absorption.\n3. Acute illness within 14 days before dosing.\n4. Severe infection within 6 months before dosing, or chronic\u002Frecurrent infections.\n5. Participant and\u002For first-degree relative with hereditary immunodeficiency.\n6. Major trauma or surgery within 3 months before dosing.\n7. History of active\u002Flatent TB or contact with an open TB case within 6 months before dosing.\n8. Positive urine drug screen.\n9. Alcohol abuse.\n10. Use of tobacco\u002Fnicotine products within 3 months before the first dose.\n11. Use of any prescription\u002Fnon-prescription drugs, herbal medicines, supplements within 14 days before first dose; or systemic corticosteroids, immunosuppressants\u002Fmodulators, hormone replacement therapy within 30 days before first dose; or any other factor affecting drug absorption, distribution, metabolism, and excretion.\n12. Consumption of caffeine-containing foods\u002Fbeverages within 48 hours before the first dose.\n13. Use of known CYP3A4 inducers\u002Finhibitors within 14 days or 5 half-lives (whichever is longer) before the first dose.\n14. Dieting, dietary therapy within 30 days before the first dose.\n15. Positive for syphilis antibody, HCV-Ab, HBsAg, HBcAb, or HIV-Ab at screening.\n16. Administration of live vaccines within 6 weeks before the first dose or planned during study or within 8 weeks after study.","50 Years",{"count":51,"type":22},104,[53],"PHASE1","This is a Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ICP-538 in Healthy Subjects",[28],"2026-06-16",{"date":58,"type":33},"2026-06-18",{"date":60,"type":33},"2026-03-13",{"date":62,"type":22},"2026-09",{"name":64,"class":65},"Beijing InnoCare Pharma Tech Co., Ltd.","INDUSTRY",{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":4,"eligibilityCriteria":72,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":73,"targetDuration":4,"studyType":75,"phases":4,"briefSummary":76,"conditions":77,"keywords":78,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":41},"100574578","using-anonymous-data-from-a-digital-tool-for-medical-history-taking-to-improve-healthcare-services-100574578","NCT06761105","Using Anonymous Data From A Digital Tool for Medical History-Taking To Improve Healthcare Services","Observation Of The Use Of Digital Tools for Medical History-Taking in Primary Care and Utilization of Anonymous Routine Data for Health Services Research","Inclusion Criteria:\n\n* all patients that use the app in a general practice that agreed to provide data\n* all ages (including children if the app is used by parent or legal guardian)\n* all complaints chosen in the app\n\nExclusion Criteria:\n\n* patients that use the app in a general practice that did not agree to provide data\n* patients that use the app in a general practice outside of the federal state Lower Saxony",{"count":74,"type":22},20,"OBSERVATIONAL","This study aims to understand how people use a mobile app that helps them record their symptoms before going to the doctor. Patients use the app on a tablet or other digital device. The app guides patients through a series of structured questions tailored to their symptoms. The data collected is then transferred to the practice's electronic record and is available to the treating doctor before and during the consultation.\n\nIn this project, anonymized usage data will be analyzed to contribute to the further development of the tool and to provide valuable insights for health services research.",[28],[79,80,81,82,83,84],"digital medical history","anonymized usage data","general practice","GP consultations","GP","health services research","2026-04-30",{"date":87,"type":33},"2026-05-06",{"date":89,"type":33},"2025-05-01",{"date":91,"type":22},"2033-12",{"name":93,"class":40},"University Hospital Goettingen",{"id":95,"slug":96,"hasResults":11,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":4,"eligibilityCriteria":100,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":101,"targetDuration":4,"studyType":23,"phases":103,"briefSummary":104,"conditions":105,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":41},"100530280","implementation-pilot-of-preoperative-cga-before-major-surgery-100530280","NCT06184724","Implementation Pilot of Preoperative CGA Before Major Surgery","Implementation Pilot of Preoperative CGA Referral Process for Older Patients Undergoing Major Surgery","Inclusion Criteria:\n\n1. Patient aged 80 or older who is scheduled for an elective inpatient major surgery\n2. Providers working in a clinic (aged 18 and older) where pCGA is performed or a related anesthesia pre-operative clinic\n3. Surgeons (adults older than 18) with a patient aged 80 or older who is scheduled for an elective inpatient major surgery\n\nExclusion criteria:\n\n* None",{"count":102,"type":22},42,[25],"The goal of this clinical trial is to test whether a new implementation package can help older adults prepare for major surgery. The main question it aims to answer is: Can the implementation package help give more people access to this resource? Participants will be in two groups: older adults who are planning a major surgery and their medical and surgical healthcare providers. The results will be compared to a historic baseline.",[106,107,28,108],"Surgery","Geriatric Assessment","Implementation Science","2026-03-18",{"date":111,"type":33},"2026-03-19",{"date":113,"type":33},"2026-01-28",{"date":115,"type":22},"2029-04",{"name":117,"class":40},"University of Wisconsin, Madison",{"id":119,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":120,"targetDuration":4,"studyType":23,"phases":121,"briefSummary":26,"conditions":122,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":129,"locationsCount":41},"100547458",{"count":21,"type":22},[25],[28],"2026-02-23",{"date":125,"type":33},"2026-02-25",{"date":127,"type":33},"2025-06-01",{"date":37,"type":22},{"name":39,"class":40},{"id":131,"slug":132,"hasResults":11,"nctId":133,"briefTitle":134,"officialTitle":135,"acronym":136,"eligibilityCriteria":137,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":138,"targetDuration":4,"studyType":75,"phases":4,"briefSummary":140,"conditions":141,"keywords":142,"overallStatus":147,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":4},"100625671","experiences-of-early-postnatal-discharge-home-as-perceived-by-mothers-and-healthcare-professionals-100625671","NCT07425665","Experiences of Early Postnatal Discharge Home as Perceived by Mothers and Healthcare Professionals","Expériences du Retour à Domicile Post-natal précoce Par Les mères et Les Professionnels de santé : enquête Qualitative Sur Les Pratiques et Besoins","BbDom94","Selection of Maternity\n\nInclusion Criteria:\n\n* Public maternity unit in Val-de-Marne offering mothers early discharge home and willing to participate\n\nExclusion Criteria:\n\n* Maternity unit opposed to participation\n\nSelection of Home Care Professionals\n\nInclusion Criteria:\n\n-Healthcare professional involved in the follow-up of early postnatal discharge home for women in Val-de-Marne and willing to participate in the study\n\nInclusion Criteria:\n\n-Person with expertise in early return home and willing to participate",{"count":139,"type":22},70,"In recent years, the average length of stay in maternity units has decreased, leading to the development of early postnatal discharge home (EPDH) programs. Postnatal follow-up is a major public health issue, as it supports the physical and psychological well-being of mothers and newborns, helps parents adjust to their new roles, and promotes health prevention and education.\n\nInternational studies show that mothers expect longer and more comprehensive follow-up, particularly regarding child development, sexuality, contraception, and returning to work. In France, EPDH has existed since the early 2000s and is offered to low-risk mothers and newborns shortly after birth, with two or three follow-up visits at home or in healthcare facilities.\n\nAs these programs are expected to expand, there is a need to better understand the experiences and needs of both mothers and healthcare professionals. This qualitative study, conducted in the Val-de-Marne department, aims to explore how they experience early discharge at individual, organizational, and medical levels. It seeks to identify the factors that contribute to positive or negative postnatal experiences and to compare local findings with existing international research.",[28],[143,144,145,146],"Perinatal care","Mothers' experiences","Healthcare professionals' experiences","Healthcare organization","NOT_YET_RECRUITING","2026-02-16",{"date":123,"type":33},{"date":151,"type":22},"2026-03",{"date":153,"type":22},"2027-08",{"name":155,"class":40},"Centre Hospitalier Intercommunal Creteil",{"id":157,"slug":158,"hasResults":11,"nctId":159,"briefTitle":160,"officialTitle":161,"acronym":4,"eligibilityCriteria":162,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":163,"targetDuration":4,"studyType":23,"phases":165,"briefSummary":166,"conditions":167,"keywords":169,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":174,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":180,"locationsCount":182},"100582512","assessing-pharmacy-technician-educational-training-for-the-provision-of-over-the-counter-hearing-aids-in-rural-alabama-and-mississippi-pharmacies-100582512","NCT06864273","Assessing Pharmacy Technician Educational Training for the Provision of Over-the-Counter Hearing Aids in Rural Alabama and Mississippi Pharmacies","Increasing Access to Hearing Healthcare: An Assessment of Pharmacy Technician Educational Training for the Provision of Over-the-Counter Hearing Aids in Rural Alabama and Mississippi Pharmacies","Inclusion Criteria:\n\n1. Pharmacy technicians licensed to practice in the state of Alabama or Mississippi.\n2. Pharmacy technicians who practice in rural communities of Alabama and Mississippi.\n3. Adults 18 years of age with mild to moderate hearing loss and who live in rural communities of Alabama or Mississippi.\n\nExclusion Criteria:\n\n1. Pharmacy technicians with hearing loss who could have prior understanding of care for those with hearing loss will not be included in the study.\n2. Adults 18 years of age or older with typical hearing will not be included in the study.\n3. Adults with hearing loss who live in urban areas of Alabama and Mississippi will not be included in the study.\n4. Participants will be excluded if they have any medical condition resulting in cognitive impairment that results in an inability to complete the study tasks (e.g., mental health condition, stroke, head injury, dementia, or Alzheimer's disease)",{"count":164,"type":22},144,[25],"Hearing loss is a major public health concern due to its negative association with emotional well-being, cognition, and physical ailments, such as diabetes. Access to audiologists and otolaryngologists in many regions across the US is poor or extremely limited. Rural populations are older, less educated, and have lower household incomes compared to populations in metropolitan areas. Also, with increasing age adults experience greater rates of hearing loss. Fortunately, the 2022 FDA Final Rule for Over-the-Counter Hearing Aids (OTC HAs) could revolutionize assess to hearing aids and hearing healthcare by allowing adults with perceived mild-to-moderate hearing loss to purchase these devices over the counter, without medical clearance or care from an audiologist. Pharmacies located in rural areas now have the option to provide OTC HAs, something previously not possible. Currently, however, there are no established guidelines for effective provision of these devices in pharmacies located in rural communities. Educating pharmacy technicians to provide basic hearing healthcare related to OTC HAs use could address a critical need and create a new care delivery model to ensure sustainable, long-term access to hearing healthcare. The long-term goal of this study is to create a sustainable interprofessional collaborative between audiologists and pharmacists for the development of a hearing healthcare model that improves access and affordability of care in rural regions across the country. The specific aims are to 1) Determine an effective approach for educating pharmacy technicians for the provision of OTC HAs in rural community pharmacies, and 2) Identify satisfaction of care provided by pharmacy technicians and initial performance with OTC HAs in adults with hearing loss living in rural communities. A stepped wedged clinical trial design will be used to study the effectiveness of a comprehensive educational training program for pharmacy technicians. Technicians from rural Alabama and Mississippi, placed within four different clusters, will participate in a multimodal training program for the purpose of developing basic clinical skills to assist adults with perceived mild-to-moderate hearing loss. Additionally, adults with hearing loss who receive clinical services from trained pharmacy technicians will be asked to report on the care they received and benefit from their OTC HAs. The central hypotheses are a) that pharmacy technician training will result in greater understanding of hearing healthcare concepts compared to no training, and b) the training will lead to successful provision of basic hearing healthcare to adults with hearing loss in rural communities. The expected outcome of this project will be the establishment of a multimodal education program, leveraging the increased access of OTC HAs, to support those with hearing loss in rural pharmacies across the county. The ability of pharmacy technicians to provide this support will dramatically increase the availability of hearing services in rural communities, which will positively impact the quality of life for those with hearing loss.",[168,28],"Bilateral Hearing Loss",[170,171,172],"pharmacy education","rural health","Aids, Hearing","2025-08-08",{"date":175,"type":33},"2025-08-13",{"date":177,"type":33},"2025-07-25",{"date":179,"type":22},"2026-08-31",{"name":181,"class":40},"University of Alabama, Tuscaloosa",2]